Resistant Gram-negative infections in the outpatient setting in Latin America

Epidemiology and Infection

Volumn 141, Issue 12, 2013, Pages 2459-2472

  Salles, Mauro José Costa ^a,m   Zurita, Jeannete ^b   Mejía, Carlos ^c   Villegas, Maria Virginia ^d   Alvarez, Carlos ^e   Bavestrello, Luis ^f   Berezin, Eitan ^a   Gotuzzo, Eduardo ^g   Guzmán Blanco, Manuel ^h   Labarca, Jaime A ⁱ   Luna, Carlos M ^j   Nouer, Simone ^k   Rodríguez Noriega, Eduardo ^l   Santos, Fortino Solórzano ⁿ  

^a Assistant Prof Internal Medicine Dept Santa Casa School of Medicine and Hospitals of São Paulo   (Brazil)

^b PONTIFICIA UNIVERSIDAD CATÓLICA DEL ECUADOR   (Ecuador)

^c Roosevelt Hospital Guatemala   (Guatemala)

^d CENTRO INTERNACIONAL DE ENTRENAMIENTO E INVESTIGACIONES MÉDICAS CIDEIM   (Colombia)

^e HOSPITAL UNIVERSITARIO SAN IGNACIO   (Colombia)

^f Unidad de Cuidados Intensivos   (Chile)

^g UNIVERSIDAD PERUANA CAYETANO HEREDIA   (Peru)

^h Department of Infectious Diseases and Microbiology   (Venezuela)

ⁱ PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^j HOSPITAL DE CLÍNICAS JOSÉ DE SAN MARTÍN   (Argentina)

^k FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^l HOSPITAL CIVIL DE GUADALAJARA FRAY ANTONIO ALCALDE   (Mexico)

^m IRMANDADE DA SANTA CASA DE MISERICÓRDIA DE SÃO PAULO   (Brazil)

ⁿ INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

more..

Author keywords

Drug resistance; Gram negative; intra abdominal infection; Latin America; outpatient; urinary tract infection

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; CEFEPIME; CEFOTAXIME; CEFOXITIN; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN; CIPROFLOXACIN; COTRIMOXAZOLE; ERTAPENEM; FOSFOMYCIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; NITROFURANTOIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULTAMICILLIN; CEPHALOSPORIN DERIVATIVE; MEROPENEM;

ABDOMINAL INFECTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIUM DETECTION; BACTERIUM ISOLATE; CLONAL VARIATION; CONCENTRATION RESPONSE; DISEASE ASSOCIATION; DISEASE SEVERITY; DISEASE SURVEILLANCE; DRUG EFFECT; ENDEMIC DISEASE; ESCHERICHIA COLI INFECTION; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ESCHERICHIA COLI; GENOTYPE; GRAM NEGATIVE INFECTION; HUMAN; KLEBSIELLA PNEUMONIAE INFECTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OUTPATIENT CARE; PHENOTYPE; PRESCRIPTION; REVIEW; RISK FACTOR; SOUTH AND CENTRAL AMERICA; TREATMENT PLANNING; URINARY TRACT INFECTION; ARTICLE; BACTERIAL STRAIN; BACTERIAL VIRULENCE; CITROBACTER; DRUG EFFICACY; DRUG SAFETY; ENTEROBACTER; ESCHERICHIA COLI; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; GEOGRAPHIC DISTRIBUTION; KLEBSIELLA PNEUMONIAE; OUTPATIENT; PROTEUS; SALMONELLA; SERRATIA; SYSTEMATIC REVIEW;

EID: 84893090675     PISSN: 09502688     EISSN: 14694409     Source Type: Journal    
DOI: 10.1017/S095026881300191X     Document Type: Review

References (67)

1. Fornasini M, et al. Trimethoprim-resistant Escherichia coli in households of children attending day care centers. Journal of Infectious Diseases 1992; 166: 326-330.
2. Reves RR, et al. Risk factors for fecal colonization with trimethoprim-resistant and multiresistant Escherichia coli among children in day-care centers in Houston, Texas. Antimicrobial Agents and Chemotherapy 1990; 34: 1429-1434.
3. McKeon DM, Calabrese JP, Bissonnette GK. Antibiotic resistant Gram-negative bacteria in rural groundwater supplies. Water Research 1995; 29: 1902-1908.
4. Woerther PL, et al. Emergence and dissemination of extended-spectrum beta-lactamase-producing Escherichia coli in the community: Lessons from the study of a remote and controlled population. Journal of Infectious Diseases 2010; 202: 515-523.
5. Hawkey PM, Jones AM. The changing epidemiology of resistance. Journal of Antimicrobial Chemotherapy 2009; 64 (Suppl. 1): 3-10.
6. Amaya E, et al. Antibiotic resistance patterns of Escherichia coli isolates from different aquatic environmental sources in León, Nicaragua. Clinical Microbiology and Infection 2012; 18: E347-354.
7. Amábile-Cuevas C. Antibiotic resistance in Mexico: A brief overview of the current status and its causes. Journal of Infection in Developing Countries 2010; 4: 126-131.
8. Reinert RR, et al. Antimicrobial susceptibility among organisms from the Asia/Pacific Rim, Europe and Latin and North America collected as part of TEST and the in vitro activity of tigecycline. Journal of Antimicrobial Chemotherapy 2007; 60: 1018-1029.
9. Eisenberg JN, et al. In-roads to the spread of antibiotic resistance: Regional patterns of microbial transmission in northern coastal Ecuador. Journal of the Royal Society Interface 2012; 9: 1029-1039.
10. Dierikx CM, et al. Occurrence and characteristics of extended-spectrum- beta-lactamase- and AmpCproducing clinical isolates derived from companion animals and horses. Journal of Antimicrobial Chemotherapy 2012; 67: 1368-1374.
11. Carattoli A, et al. Extended-spectrum beta-lactamases in Escherichia coli isolated from dogs and cats in Rome, Italy, from 2001 to 2003. Antimicrobial Agents and Chemotherapy 2005; 49: 833-835.
12. Dierikx C, et al. Increased detection of extended spectrum beta-lactamase producing Salmonella enterica and Escherichia coli isolates from poultry. Veterinary Microbiology 2010; 145: 273-278.
13. Hunter PA, et al. Antimicrobial-resistant pathogens in animals and man: Prescribing, practices and policies. Journal of Antimicrobial Chemotherapy 2010; 65 (Suppl. 1): 3-17.
14. Kojima A, et al. Extended-spectrum-beta-lactamaseproducing Escherichia coli strains isolated from farm animals from 1999 to 2002: Report from the Japanese Veterinary Antimicrobial Resistance Monitoring Program. Antimicrobial Agents and Chemotherapy 2005; 49: 3533-3537.
15. Rogers BA, Sidjabat HE, Paterson DL. Escherichia coli O25b-ST131: A pandemic, multiresistant, communityassociated strain. Journal of Antimicrobial Chemotherapy 2011; 66: 1-14.
16. Moreno A, et al. Extended-spectrum beta-lactamases belonging to CTX-M group produced by Escherichia coli strains isolated from companion animals treated with enrofloxacin. Veterinary Microbiology 2008; 129: 203-208.
17. Rossi F. The challenges of antimicrobial resistance in Brazil. Clinical Infectious Diseases 2011; 52: 1138-1143.
18. Baquero F, et al. In vitro susceptibilities of aerobic and facultatively anaerobic gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2005 results from Study for Monitoring Antimicrobial Resistance Trends (SMART). Surgical Infections (Larchmont) 2009; 10: 99-104.
19. Andrade SS, et al. Increased resistance to first-line agents among bacterial pathogens isolated from urinary tract infections in Latin America: Time for local guidelines Memórias do Instituto Oswaldo Cruz 2006; 101: 741-748.
20. Bours PH, et al. Increasing resistance in communityacquired urinary tract infections in Latin America, five years after the implementation of national therapeutic guidelines. International Journal of Infectious Diseases 2010; 14: E770-e774.
21. Casellas JM; Antimicrobial Resistance Committee. Results of the 7th Survey of the Antimicrobial Resistance Committee of the Pan American Association of Infectious Diseases. Revista Panamericana de Infectología 2006; 8: 48-55.
22. Alvarez E, Espino M, Contreras R. Antimicrobial susceptibility of Escherichia coli urinary tract isolates by the DIRAMIC system. Revista Panamericana de Infectología 2006; 8: 10-15.
23. Gales AC, Sader HS, Jones RN. Urinary tract infection trends in Latin American hospitals: Report from the SENTRY antimicrobial surveillance program (1997- 2000). Diagnostic Microbiology & Infectious Disease 2002; 44: 289-299.
24. Guzman-Blanco M, Casellas JM, Sader HS. Bacterial resistance to antimicrobial agents in Latin America. The giant is awakening. Infectious Disease Clinics of North America 2000; 14: 67-81.
25. Zurita J. Urinary E. coli: Resistance trend in Ecuador from 1999 to 2007. Revista Ecuatoriana de Ginecologia y Obstetricia 2009; 15: 29-35.
26. Pitout JD, Laupland KB. Extended-spectrum betalactamase- producing Enterobacteriaceae: An emerging public-health concern. Lancet Infectious Diseases 2008; 8: 159-166.
27. Rodríguez-Baño J, et al. Bacteremia due to extendedspectrum beta-lactamase-producing Escherichia coli in the CTX-M era: A new clinical challenge. Clinical Infectious Diseases 2006; 43: 1407-1414.
28. O'Brien TF, Stelling J. Integrated multilevel surveillance of the world's infecting microbes and their resistance to antimicrobial agents. Clinical Microbiology Reviews 2011; 24: 281-295.
29. Bradford PA. Extended-spectrum beta-lactamases in the 21st century: Characterization, epidemiology, and detection of this important resistance threat. Clinical Microbiology Reviews 2001; 14: 933-951.
30. Minarini LA, et al. Prevalence of community-occurring extended spectrum beta-lactamase-producing Enterobacteriaceae in Brazil. Current Microbiology 2007; 54: 335-341.
31. Cantón R, Coque TM. The CTX-M beta-lactamase pandemic. Current Opinion in Microbiology 2006; 9: 466-475.
32. Mattar S, Martinez P. Emergence of antimicrobial resistance to extended-spectrum-lactamases (ESBL): Detection, clinic impact and epidemiology. Infectio 2007; 11: 23-35.
33. Cantón R, González-Alba JM, Galán JC. CTX-M enzymes: Origin and diffusion. Frontiers in Microbiology 2012; 3: 110.
34. Ben-Ami R, et al. A multinational survey of risk factors for infection with extended-spectrum beta-lactamaseproducing Enterobacteriaceae in nonhospitalized patients. Clinical Infectious Diseases 2009; 49: 682-690.
35. Casellas JM. Antibacterial drug resistance in Latin America: Consequences for infectious disease control. Revista Panamericana de Salud Pública 2011; 30: 519-528.
36. Hawser SP, et al. Epidemiologic trends, occurrence of extended-spectrum beta-lactamase production, and performance of ertapenem and comparators in patients with intra-abdominal infections: Analysis of global trend data from 2002-2007 from the SMART study. Surgical Infections (Larchmont) 2010; 11: 371-378.
37. Rocha JL, Tuon FF, Johnson Jr. Sex, drugs, bugs, and age: Rational selection of empirical therapy for outpatient urinary tract infection in an era of extensive antimicrobial resistance. Brazilian Journal of Infectious Diseases 2012; 16: 115-121.
38. Pan-American Health Organization. Annual Report of the Network of Monitoring/Surveillance of Antimicrobial Resistance. Lima, Peru, 3 and 4 December 2009. (http://new.paho.org/hq/index.phpoption=com-docman& task=doc-view&gid=14876&Itemid=3938
39. Pan-American Health Organization. Annual Report of the Latin American Network for Surveillance of Antimicrobial Resistance. San José, Costa Rica, 29-30 November, 1 December, 2010.
40. Gordillo MR, Mejía CR. Analysis of resistance of urinary cultures 2005-2010, Roosevelt Hospital, Guatemala City. Revista del Colegio de Medicos y Cirujanos de Guatemala 2011; VI: 51-56.
41. Silva FO, et al. Results of antimicrobial susceptibility surveillance in Chile: Consolidating a network. Revista Chilena de Infectología 2011; 28: 19-27.
42. Villegas MV, et al. Increasing prevalence of extendedspectrum- beta-lactamase among Gram-negative bacilli in Latin America - 2008 update from the Study for Monitoring Antimicrobial Resistance Trends (SMART). Brazilian Journal of Infectious Diseases 2011; 15: 34-39.
43. Hawser SP, et al. Low frequency of ertapenem-resistant intra-abdominal isolates of Escherichia coli from Latin America: Susceptibility, ESBL-occurrence, and molecular characterisation (SMART 2008-2009). Journal of Chemotherapy 2012; 24: 6-11.
44. van der Starre WE, et al. Risk factors for fluoroquinolone-resistant Escherichia coli in adults with community-onset febrile urinary tract infection. Journal of Antimicrobial Chemotherapy 2011; 66: 650-656.
45. Cohen-Nahum K, et al. Urinary tract infections caused by multi-drug resistant Proteus mirabilis: Risk factors and clinical outcomes. Infection 2010; 38: 41-46.
46. Wu UI, et al. Risk factors for bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli. Journal of Microbiology, Immunology and Infection 2010; 43: 310-316.
47. Cassier P, et al. Cephalosporin and fluoroquinolone combinations are highly associated with CTX-M beta-lactamase-producing Escherichia coli: A casecontrol study in a French teaching hospital. Clinical Microbiology and Infection 2011; 17: 1746-1751.
48. Paterson DL, et al. International prospective study of Klebsiella pneumoniae bacteremia: Implications of extended-spectrum beta-lactamase production in nosocomial infections. Annals of Internal Medicine 2004; 140: 26-32.
49. Saely S, et al. Investigating the impact of the definition of previous antibiotic exposure related to isolation of extended spectrum beta-lactamase-producing Klebsiella pneumoniae. American Journal of Infection Control 2011; 39: 390-395.
50. Lahey Clinic. OXA-type beta-lactamases (http://www.lahey.org/studies/ other.asp). Accessed 13 March 2013.
51. Mendes RE, et al. Ability of Latin America laboratories to detect antimicrobial resistance patterns: Experience of the SENTRY Antimicrobial Surveillance Program (1997-2000). Brazilian Journal of Infectious Diseases 2003; 7: 282-289.
52. Cormican MG, Marshall SA, Jones RN. Detection of extended-spectrum beta-lactamase (ESBL)-producing strains by the Etest ESBL screen. Journal of Clinical Microbiology 1996; 34: 1880-1884.
53. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing (2010). M100-S20. CLSI, Wayne, PA.
54. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. 12th informational supplement. M100-S12. Wayne, PA: National Committee for Clinical Laboratory Standards, 2002.
55. Wiegand I, et al. Detection of extended-spectrum beta-lactamases among Enterobacteriaceae by use of semiautomated microbiology systems and manual detection procedures. Journal of Clinical Microbiology 2007; 45: 1167-1174.
56. Manges AR, et al. Endemic and epidemic lineages of Escherichia coli that cause urinary tract infections. Emerging Infectious Disease Journal 2008; 14: 1575-1583.
57. Coque TM, et al. Dissemination of clonally related Escherichia coli strains expressing extended-spectrum beta-lactamase CTX-M-15. Emerging Infectious Diseases 2008; 14: 195-200.
58. Pitout JD, et al. Molecular characteristics of extendedspectrum- beta-lactamase-producing Escherichia coli isolates causing bacteremia in the Calgary Health Region from 2000 to 2007: Emergence of clone ST131 as a cause of community-acquired infections. Antimicrobial Agents and Chemotherapy 2009; 53: 2846-2851.
59. Leal AL, et al. Emergence of resistance to third generation cephalosporins by Enterobacteriaceae causing community-onset urinary tract infections in hospitals in Colombia. Enfermedades Infecciosas y Microbiologia Clinica. Published online: 14 June 2012. doi.org/10•1016/j.eimc. 2012•04•007.
60. Peirano G, et al. Molecular characteristics of extendedspectrum beta-lactamase-producing Escherichia coli from Rio de Janeiro, Brazil. Clinical Microbiology and Infection 2011; 17: 1039-1043.
61. Ruiz SJ, et al. First characterization of CTX-M- 15-producing Escherichia coli ST131 and ST405 clones causing community-onset infections in South America. Journal of Clinical Microbiology 2011; 49: 1993-1996.
62. Martinez P, Garzón D, Mattar S. CTX-M-producing Escherichia coli and Klebsiella pneumoniae isolated from community-acquired urinary tract infections in Valledupar, Colombia. Brazilian Journal of Infectious Diseases 2012; 16: 420-425.
63. Dias RC, et al. Clonal composition of Escherichia coli causing community-acquired urinary tract infections in the State of Rio de Janeiro, Brazil. Microbial Drug Resistance 2009; 15: 303-308.
64. Queiroz ML, et al. Characterization of extendedspectrum beta-lactamases, antimicrobial resistance genes, and plasmid content in Escherichia coli isolates from different sources in Rio de Janeiro, Brazil. Diagnostic Microbiology & Infectious Disease 2012; 74: 91-94.
65. Millán B, et al. CTX-M-14 beta-lactamase-producing Citrobacter freundii isolated in Venezuela. Annals of Clinical Microbiology and Antimicrobials 2011; 10: 22.
66. Gupta K, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clinical Infectious Diseases 2011; 52: E103-120.
67. Center for Disease Dynamics Economics & Policy (CDDEP). Exploring ResistanceMap: The rise of fluoroquinolone resistance. Available online at: Http://www.cddep.org/blog/posts/exploring-resistancemap-rise- fluoroquinolone-resistance-part-1. Accessed 10 January 2013.